# A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

> **NCT06641466** · PHASE3 · RECRUITING · sponsor: **Pfizer** · enrollment: 723 (estimated)

## Conditions studied

- Menstrual Migraine

## Interventions

- **DRUG:** Rimegepant
- **DRUG:** Placebo Comparator
- **DRUG:** Standard of Care
- **DRUG:** Rimegepant

## Key facts

- **NCT ID:** NCT06641466
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-11
- **Primary completion:** 2026-11-29
- **Final completion:** 2027-03-30
- **Target enrollment:** 723 (ESTIMATED)
- **Last updated:** 2026-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06641466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06641466, "A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT06641466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*